Use of direct oral anticoagulants in antiphospholipid syndrome: Reply
Journal of Thrombosis and Haemostasis2020Vol. 18(1), pp. 259–261
Citations Over Time
Related Papers
- → Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial(2015)86 cited
- → Primary antiphospholipid syndrome in a child with lower extremity arterial thrombosis(1994)8 cited
- Raps (rivaroxaban in antiphospholipid syndrome): a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE(2015)
- → Intracardiac Thrombosis Due to Antiphospholipid Syndrome(2016)
- → Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome(2019)